We are upgrading the repository! A content freeze is in effect until November 22nd, 2024 - no new submissions will be accepted; however, all content already published will remain publicly available. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available soon. Note that any new user accounts created after September 22, 2024 will need to be recreated by the user in November after our migration is completed.
Name:
Revised main Manuscript J Inv ...
Size:
314.3Kb
Format:
PDF
Description:
Final Accepted Manuscript
Author
Tolouian, RaminMulla, Zuber D
Jamaati, Hamidreza
Babamahmoodi, Abdolreza
Marjani, Majid
Eskandari, Raha
Dastan, Farzaneh
Affiliation
Renal Section, Southern Arizona VA Health Care System, University of ArizonaIssue Date
2021-03-15
Metadata
Show full item recordPublisher
BMJ Publishing GroupCitation
Tolouian, R., Mulla, Z. D., Jamaati, H., Babamahmoodi, A., Marjani, M., Eskandari, R., & Dastan, F. (2021). Effect of bromhexine in hospitalized patients with COVID-19. Journal of Investigative Medicine.Rights
© American Federation for Medical Research 2021.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controlling influenza and parainfluenza infection; however, its efficacy in COVID-19 is controversial. Methods: A group of hospitalized patients with confirmed COVID-19 pneumonia were randomized using 1:1 allocation to either standard treatment lopinavir/ritonavir and interferon beta-1a or bromhexine 8 mg four times a day in addition to standard therapy. The primary outcome was clinical improvement within 28 days, and the secondary outcome measures were time to hospital discharge, all-cause mortality, duration of mechanical ventilation, the temporal trend in 2019-nCoV reverse transcription-polymerase chain reaction positivity and the frequency of adverse drug events within 28 days from the start of medication. Results: A total of 111 patients were enrolled in this randomized clinical trial and data from 100 patients (48 patients in the treatment arm and 52 patients in the control arm) were analyzed. There was no significant difference in the primary outcome of this study, which was clinical improvement. There was no significant difference in the average time to hospital discharge between the two arms. There were also no differences observed in the mean intensive care unit stay, frequency of intermittent mandatory ventilation, duration of supplemental oxygenation or risk of death by day 28 noted between the two arms. Conclusion: Bromhexine is not an effective treatment for hospitalized patients with COVID-19. The potential prevention benefits of bromhexine in asymptomatic postexposure or with mild infection managed in the community remain to be determined.ISSN
1081-5589EISSN
1708-8267Version
Final accepted manuscriptae974a485f413a2113503eed53cd6c53
10.1136/jim-2020-001747